Statute Details
- Title: Health Products (Licensing of Retail Pharmacies) Regulations 2016
- Act Code: HPA2007-S330-2016
- Type: Subsidiary Legislation (SL)
- Authorising Act: Health Products Act (Cap. 122D), sections 71 and 72
- Enacting Authority: Health Sciences Authority (HSA), with Minister for Health approval
- Citation: No. S 330
- Commencement: 1 November 2016
- Current version reference: Current version as at 27 March 2026 (with amendments including S 692/2024 effective 4 September 2024)
- Key provisions (from extract): Regulation 2 (definitions); Regulation 3 (requirements for retail supply); Regulation 4 (telepharmacy services); Regulation 5 (application for pharmacy licence); Regulation 6 (suspension/revocation/cancellation); Regulation 7 (changes affecting licence); Regulation 8 (routine inspections); Regulation 9 (deleted)
- Schedules: First Schedule (specified health products); Second Schedule (repealed)
What Is This Legislation About?
The Health Products (Licensing of Retail Pharmacies) Regulations 2016 (“Retail Pharmacies Regulations”) form a regulatory framework under Singapore’s Health Products Act for the licensing and oversight of retail pharmacies. In practical terms, the Regulations control who may sell certain categories of health products to the public, where and how those products may be supplied, and what record-keeping and access controls must be in place.
The Regulations are particularly important because they translate the Health Products Act’s licensing and supply restrictions into operational requirements for retail pharmacy businesses. They define key terms (such as “retail pharmacy services”, “specified health products”, and “telepharmacy services”), set conditions for lawful retail supply, and empower the Health Sciences Authority (HSA) to inspect pharmacies routinely. They also address pharmacy licensing procedures and the consequences of non-compliance, including suspension, revocation, and cancellation of approvals.
For practitioners, the Regulations should be read alongside the Health Products Act and the broader healthcare regulatory landscape, including the Healthcare Services Act 2020 (for definitions and certain service licensing concepts) and the Pharmacists Registration regime. The Regulations also interact with other health-product rules (for example, classification of medicines and rules on prescription-only medicines), meaning that compliance is not merely “licence possession” but a structured set of operational controls.
What Are the Key Provisions?
1. Licensing and the “specified health products” gatekeeping model (Regulation 3)
The core compliance rule appears in Regulation 3. It provides that, for the purposes of section 17 of the Health Products Act, a person must not supply by retail sale any “specified health product” unless strict conditions are met. The “specified health products” are listed in the First Schedule to the Act (as referenced in the Regulations’ definitions and schedules). This is a classic regulatory “gate” mechanism: if the product is within the specified list, the supplier must meet licensing and operational requirements.
Under Regulation 3(1), lawful retail supply requires, among other things, that the person is the holder of a pharmacy licence; that the supply is carried out at or from the retail pharmacy specified in that licence; and that the supply is performed by an in-store pharmaceutical officer (or, in the absence of that officer, via a “special mode” only with prior approval of the Authority). This ensures that specified products are not sold casually or by unqualified staff, and that there is a controlled mechanism for any temporary deviation.
2. Record-keeping and retention (Regulation 3(1)(d)–(e))
Regulation 3 also imposes a record-keeping obligation. A proper record of every supply of the specified health product must be made by the in-store pharmaceutical officer (or using the approved special mode). The record must be kept for at least two years after the date of supply. This is a significant compliance requirement for pharmacy operators because it affects systems, audit readiness, and data governance. Practitioners advising pharmacies should ensure that record formats, storage, and retrieval processes can withstand inspection and enforcement scrutiny.
3. Access control to specified products and controlled drugs (Regulation 3(1)(f)–(g))
Regulation 3 further requires that only an in-store pharmaceutical officer may have access to specified health products stored at the retail pharmacy (with an express carve-out for controlled drugs). For controlled drugs, only a qualified pharmacist may have access. These provisions are designed to prevent diversion, unauthorised handling, and unsafe dispensing practices. From a legal risk perspective, access control is often where operational breaches occur (e.g., keys, storage cabinets, stock room access, or staff handover practices). Lawyers advising on compliance should focus on governance: who can access what, under what circumstances, and how access is documented or controlled.
4. Telepharmacy services and remote provision (Regulation 4)
The Regulations also address telepharmacy services, defined as the provision of retail pharmacy services by a qualified pharmacist at a retail pharmacy through a computer or video/audio link. While the extract provided does not reproduce the full text of Regulation 4, its inclusion in the legislative structure indicates that the Regulations contemplate remote or technology-enabled pharmacy service models. Practitioners should treat telepharmacy as a regulated mode of service delivery that likely comes with conditions relating to pharmacist involvement, patient interaction, and compliance with the same supply, record, and access principles.
5. Pharmacy licensing process and enforcement consequences (Regulations 5–7)
Regulations 5 to 7 address the lifecycle of a pharmacy licence. Regulation 5 provides for the application for a pharmacy licence, including administrative requirements and (as reflected in the definitions) the use of an “application fee” specified in the Health Products (Fees) Regulations 2022. Regulation 6 provides for suspension and revocation of a pharmacy licence and cancellation of approval (including likely approvals relevant to special modes of supply). Regulation 7 addresses changes affecting the pharmacy licence, which is crucial because pharmacy businesses may undergo changes in premises, management, staffing, or operational arrangements. Legal advice should therefore include a “change notification” compliance strategy: what changes trigger regulatory notification, what approvals are required, and what happens if changes occur without authorisation.
6. Routine inspections by the Authority (Regulation 8)
Regulation 8 empowers the HSA to conduct routine inspections of retail pharmacies to ensure compliance with the Regulations. This is a direct enforcement mechanism. Practitioners should assume that inspections will test not only licence validity and premises compliance, but also record-keeping, access controls, and whether specified products are supplied only under the permitted staffing and operational conditions. The existence of routine inspections also means that compliance should be continuous and documented, not merely “prepared for audit”.
How Is This Legislation Structured?
The Regulations are structured as a set of operational rules supported by definitions and schedules:
(1) Regulation 1 sets out the citation and commencement date (1 November 2016).
(2) Regulation 2 contains definitions. It is notable for cross-referencing other statutes and subsidiary legislation, including the Healthcare Services Act 2020 (for meanings of “approved conveyance”, “approved permanent premises”, and “permanent premises”), the Healthcare Services (Collaborative Prescribing Service) Regulations 2023 (for “collaborative prescribing practitioner”), and the Pharmacists Registration framework (for “qualified pharmacist”). It also defines “telepharmacy services” and “retail pharmacy services”.
(3) Regulation 3 sets the principal restrictions on retail supply of specified health products, including licensing, staffing, record-keeping, and access control.
(4) Regulation 4 addresses telepharmacy services.
(5) Regulation 5 provides for applications for a pharmacy licence.
(6) Regulation 6 provides for suspension/revocation of licences and cancellation of approvals.
(7) Regulation 7 addresses changes affecting the licence.
(8) Regulation 8 provides for routine inspections.
(9) Regulation 9 is deleted.
The First Schedule lists “specified health products”, which is central to determining when Regulation 3 applies. The Second Schedule concerns repealed provisions.
Who Does This Legislation Apply To?
The Regulations apply primarily to persons who supply “specified health products” by retail sale—most directly, retail pharmacy businesses operating at or from licensed premises. The obligations in Regulation 3 are framed around the “person” who supplies, but in practice the conditions require that the supplier holds a pharmacy licence and that supply is carried out by authorised personnel (in-store pharmaceutical officer or, for controlled drugs, a qualified pharmacist).
The Regulations also apply to the Health Sciences Authority in its inspection and enforcement role, and they interact with other regulated healthcare service models (including telepharmacy and, through definitions, collaborative prescribing and healthcare service licensing concepts). For businesses, the practical takeaway is that compliance is not limited to the pharmacy licence holder; it extends to staffing arrangements, operational controls, and record systems used by the pharmacy.
Why Is This Legislation Important?
For practitioners, the Retail Pharmacies Regulations are important because they operationalise the Health Products Act’s restrictions into concrete compliance duties. The Regulations create a structured compliance environment: a pharmacy licence is necessary but not sufficient. A pharmacy must also ensure that specified products are supplied only under authorised staffing conditions, within the licensed premises, and with proper records and access controls.
From an enforcement perspective, the combination of (i) routine inspections (Regulation 8), (ii) suspension/revocation and cancellation powers (Regulation 6), and (iii) detailed operational requirements (Regulation 3) means that breaches can have immediate and serious consequences. Lawyers advising pharmacy operators should therefore treat these Regulations as a compliance “checklist” for day-to-day operations: staffing compliance, record retention, secure storage, and controlled handling of specified products and controlled drugs.
Finally, the inclusion of telepharmacy services signals that the regulatory framework is designed to accommodate modern service delivery models while maintaining safety and accountability. Practitioners should be alert to how telepharmacy interacts with the same supply restrictions and record/access requirements, and should ensure that technology-enabled workflows do not create compliance gaps (for example, around who is considered to be supplying, how records are captured, and how controlled drugs are handled).
Related Legislation
- Health Products Act (Cap. 122D)
- Health Products (Fees) Regulations 2022 (application fee referenced in Regulation 2)
- Drugs Act 1973
- Healthcare Services Act 2020
- Healthcare Services (Collaborative Prescribing Service) Regulations 2023
- Pharmacists Registration Act 2007
- Pharmacists Registration (Practising Certificates) Regulations 2008
- Dental Registration Act 1999
Source Documents
This article provides an overview of the Health Products (Licensing of Retail Pharmacies) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.